 Jenna Demedis
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 13 | 2026 | 337 | 3.330 |
Why?
| | Sexual Dysfunction, Physiological | 6 | 2026 | 75 | 2.590 |
Why?
| | Neoplasms | 22 | 2026 | 2906 | 2.520 |
Why?
| | Hyperglycemia | 4 | 2023 | 379 | 1.250 |
Why?
| | Sexual Health | 3 | 2026 | 68 | 1.140 |
Why?
| | Hodgkin Disease | 2 | 2023 | 171 | 0.930 |
Why?
| | Lymphoma | 2 | 2023 | 237 | 0.920 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2022 | 699 | 0.840 |
Why?
| | Patient Reported Outcome Measures | 3 | 2024 | 497 | 0.780 |
Why?
| | Adolescent | 29 | 2026 | 22529 | 0.700 |
Why?
| | Young Adult | 20 | 2026 | 14218 | 0.670 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 297 | 0.590 |
Why?
| | Survivorship | 2 | 2025 | 57 | 0.580 |
Why?
| | Child | 29 | 2026 | 22707 | 0.550 |
Why?
| | Hypoglycemia | 2 | 2022 | 479 | 0.470 |
Why?
| | Child, Preschool | 12 | 2026 | 11853 | 0.390 |
Why?
| | Medical Oncology | 3 | 2026 | 339 | 0.390 |
Why?
| | Sarcoma, Ewing | 2 | 2025 | 103 | 0.360 |
Why?
| | Humans | 39 | 2026 | 145474 | 0.340 |
Why?
| | Blood Glucose | 4 | 2023 | 2341 | 0.330 |
Why?
| | Eye Neoplasms | 1 | 2021 | 30 | 0.330 |
Why?
| | Risk Factors | 8 | 2026 | 10885 | 0.310 |
Why?
| | Male | 23 | 2026 | 72842 | 0.310 |
Why?
| | Tinnitus | 1 | 2021 | 69 | 0.310 |
Why?
| | Infant | 8 | 2026 | 10077 | 0.310 |
Why?
| | Adult | 15 | 2026 | 40777 | 0.300 |
Why?
| | Castleman Disease | 1 | 2019 | 16 | 0.290 |
Why?
| | Quality of Life | 6 | 2024 | 3204 | 0.270 |
Why?
| | Female | 24 | 2026 | 78844 | 0.270 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2022 | 701 | 0.270 |
Why?
| | Survivors | 3 | 2023 | 523 | 0.260 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 441 | 0.260 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 148 | 0.260 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 191 | 0.260 |
Why?
| | Leukemia | 1 | 2019 | 246 | 0.250 |
Why?
| | Immunoconjugates | 1 | 2018 | 138 | 0.250 |
Why?
| | Mass Screening | 2 | 2026 | 1360 | 0.240 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2017 | 98 | 0.240 |
Why?
| | Multicenter Studies as Topic | 2 | 2025 | 412 | 0.230 |
Why?
| | Sex Education | 1 | 2026 | 34 | 0.230 |
Why?
| | Nuclear Proteins | 1 | 2021 | 740 | 0.230 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 641 | 0.230 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 561 | 0.230 |
Why?
| | Workload | 1 | 2017 | 168 | 0.220 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 66 | 0.220 |
Why?
| | Pregnancy, Unplanned | 1 | 2025 | 48 | 0.220 |
Why?
| | Clonal Evolution | 1 | 2025 | 47 | 0.210 |
Why?
| | Retrospective Studies | 7 | 2023 | 17291 | 0.210 |
Why?
| | Febrile Neutropenia | 1 | 2023 | 6 | 0.200 |
Why?
| | Mixed Tumor, Malignant | 1 | 2023 | 4 | 0.200 |
Why?
| | Symptom Assessment | 1 | 2024 | 136 | 0.200 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 134 | 0.200 |
Why?
| | Perception | 1 | 2026 | 378 | 0.200 |
Why?
| | Adipose Tissue, Brown | 1 | 2023 | 60 | 0.190 |
Why?
| | Infant, Newborn | 4 | 2026 | 6447 | 0.190 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2023 | 161 | 0.190 |
Why?
| | Urinary Tract | 1 | 2023 | 47 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2025 | 259 | 0.180 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 76 | 0.180 |
Why?
| | Testicular Neoplasms | 1 | 2023 | 111 | 0.180 |
Why?
| | Patients | 1 | 2024 | 183 | 0.180 |
Why?
| | Positron-Emission Tomography | 1 | 2023 | 343 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 362 | 0.170 |
Why?
| | Lung Diseases | 1 | 2018 | 780 | 0.170 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 562 | 0.170 |
Why?
| | Rhabdoid Tumor | 1 | 2023 | 102 | 0.170 |
Why?
| | Bacterial Infections | 1 | 2023 | 246 | 0.170 |
Why?
| | Qualitative Research | 3 | 2023 | 1674 | 0.170 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 190 | 0.170 |
Why?
| | Pediatrics | 2 | 2026 | 1121 | 0.170 |
Why?
| | Algorithms | 1 | 2019 | 1845 | 0.170 |
Why?
| | Bacteremia | 1 | 2023 | 222 | 0.170 |
Why?
| | Incidence | 2 | 2023 | 2923 | 0.170 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 83 | 0.170 |
Why?
| | Internet | 1 | 2026 | 689 | 0.170 |
Why?
| | Prognosis | 5 | 2025 | 4316 | 0.160 |
Why?
| | Electronic Health Records | 1 | 2019 | 1196 | 0.160 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 46 | 0.160 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1321 | 0.160 |
Why?
| | Guideline Adherence | 1 | 2025 | 586 | 0.160 |
Why?
| | Registries | 1 | 2019 | 2406 | 0.160 |
Why?
| | Curriculum | 1 | 2017 | 1070 | 0.150 |
Why?
| | Mutation | 1 | 2021 | 4075 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2024 | 1061 | 0.140 |
Why?
| | Hospitalization | 2 | 2026 | 2460 | 0.140 |
Why?
| | Overweight | 1 | 2023 | 614 | 0.130 |
Why?
| | Glucose | 1 | 2023 | 1048 | 0.130 |
Why?
| | Sepsis | 1 | 2023 | 664 | 0.130 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 2214 | 0.130 |
Why?
| | Health Promotion | 1 | 2023 | 775 | 0.120 |
Why?
| | Internship and Residency | 1 | 2017 | 1267 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1371 | 0.110 |
Why?
| | Primary Health Care | 1 | 2025 | 1735 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2026 | 2381 | 0.100 |
Why?
| | Semen | 1 | 2023 | 24 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3922 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2025 | 5423 | 0.090 |
Why?
| | Survival Rate | 2 | 2019 | 2090 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2187 | 0.080 |
Why?
| | Prevalence | 2 | 2021 | 2865 | 0.080 |
Why?
| | Computer Systems | 1 | 2020 | 55 | 0.080 |
Why?
| | Radiotherapy | 1 | 2021 | 204 | 0.080 |
Why?
| | Calibration | 1 | 2020 | 152 | 0.080 |
Why?
| | Obesity | 1 | 2023 | 3116 | 0.070 |
Why?
| | Anti-Bacterial Agents | 3 | 2025 | 1923 | 0.070 |
Why?
| | Herpesvirus 8, Human | 1 | 2019 | 67 | 0.070 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 130 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1266 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2019 | 344 | 0.070 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 465 | 0.070 |
Why?
| | Survival Analysis | 1 | 2020 | 1374 | 0.060 |
Why?
| | Grounded Theory | 1 | 2017 | 44 | 0.060 |
Why?
| | Middle Aged | 2 | 2026 | 36215 | 0.060 |
Why?
| | Disease Management | 1 | 2019 | 653 | 0.060 |
Why?
| | Equivalence Trials as Topic | 1 | 2025 | 35 | 0.060 |
Why?
| | Recurrence | 1 | 2018 | 1138 | 0.050 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 81 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2020 | 11772 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1471 | 0.050 |
Why?
| | Tennessee | 1 | 2013 | 57 | 0.050 |
Why?
| | Focus Groups | 1 | 2017 | 569 | 0.050 |
Why?
| | Critical Pathways | 1 | 2024 | 109 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 442 | 0.050 |
Why?
| | Fatigue | 1 | 2024 | 364 | 0.050 |
Why?
| | Fever | 1 | 2023 | 319 | 0.040 |
Why?
| | Fertility | 1 | 2023 | 173 | 0.040 |
Why?
| | Age Factors | 1 | 2019 | 3342 | 0.040 |
Why?
| | Prospective Studies | 2 | 2025 | 8057 | 0.040 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 30 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 31 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 734 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 119 | 0.040 |
Why?
| | Interpersonal Relations | 1 | 2023 | 397 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 870 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2025 | 777 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 212 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1443 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1963 | 0.030 |
Why?
| | Personal Satisfaction | 1 | 2020 | 219 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1767 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1041 | 0.030 |
Why?
| | Inflammation | 1 | 2019 | 2878 | 0.030 |
Why?
| | Communication | 1 | 2023 | 975 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1581 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 485 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2013 | 3623 | 0.030 |
Why?
| | Time Factors | 1 | 2017 | 7123 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 961 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3413 | 0.020 |
Why?
| | Transcription Factors | 1 | 2021 | 1734 | 0.020 |
Why?
| | Pregnancy | 1 | 2025 | 7202 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 6066 | 0.020 |
Why?
|
|
Demedis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|